Scott Tarriff, CEO at EAGLE PHARMACEUTICALS, INC. (EGRX), sold 54,336 shares at $39.70 ($2.1M) on 2019-01-03, disclosed to the SEC on 2019-01-04.
Open-market sale of $2.1M EGRX by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.30 | 6,500 | $255K | 11.9% |
| 2 | $39.30 | 6,500 | $255K | 11.9% |
| 3 | $40.03 | 8,500 | $340K | 15.9% |
| 4 | $39.04 | 10,597 | $414K | 19.3% |
| 5 | $39.04 | 10,597 | $414K | 19.3% |
| 6 | $39.70 | 5,670 |
| $225K |
| 10.5% |
| 7 | $39.70 | 5,670 | $225K | 10.5% |
| 8 | $40.57 | 302 | $12K | 0.6% |
| Total | $39.40 avg | 54,336 | $2.1M | 100% |
| Filing → |
| EGRX | SELL | 2023-05-18 | $300K | — | Filing → |
| EGRX | SELL | 2023-05-15 | $1.2M | — | Filing → |
| EGRX | SELL | 2019-04-03 | $2.5M | — | Filing → |